Biomagnetics Diagnostics Corp. is an advanced medical device and biotechnology company with a revolutionary diagnostics system and test kit testing technology for HIV, Hepatitis, H-Pylori, HPV, Tuberculosis and many other viruses, bacterium’s, toxins and diseases. The company focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, instead of the antibodies produced by the body’s immune system which may take anywhere from weeks to months to appear.

The company intends to follow the lead of established Western drugmakers and biotechs Merck & Co. (MRK), Wyeth (WYE), Eli Lilly & Co. (LLY), Schering-Plough (SGP), Novartis (NVS), Sanofi-Aventis (SNY), Genentech (DNA), Bristol Meyers Squibb (BMYS) and many others that are ramping up investments in China, India and Singapore. The company is currently working to establish a separate Chinese operating company that it intends to apply for listing on the Shenzhen or Hong Kong stock exchange.

Biomagnetics is also currently

...

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

...

Nutra Pharma Corp.

(Public, OTC:NPHC)

StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Wednesday August 26, 2009

PennyOmega.com Stock Report!

**************************************************************

Raser Technologies, Inc. (NYSE: RZ), an energy technology company, announced results from a recent test drive demonstrating over 50 miles of all-electric range by its electric Hummer H3E during a preliminary road test.

TIBCO Software Inc. (NASDAQ: TIBX), today announced the general availability of TIBCO Collaborative Information Manager(TM) version 7.2.1 — the first enterprise master data management (MDM) platform to provide out-of-the box functionality that offers customers powerful new tools to address their data integrity challenges using machine intelligence.

Guardian Technologies International, Inc. (OTCBB: GDTI) today announced that its Software Quality Assurance Team has completed all unit, component, integration,

...

Highlights include Gilead Sciences (GILD), AstraZeneca (AZN), Sanofi-Aventis (SNY) and Genzyme (GENZ).Last week, President Obama nominated Margaret "Peggy" Hamburg, a former New York City Health Commissioner, to lead the U.S. Food and Drug Administration (FDA). Hamburg's appointment must be confirmed by Congress. The president also named Baltimore Health Commissioner Joshua Sharfstein as FDA deputy commissioner.Hamburg earned her M.D. from Harvard Medical School and completed her training at the New York Hospital/Cornell University Medical Center. She did research in neuroscience at Rockefeller University in New York from 1985 to 1986, and in neuropharmacology at the National Institute of Mental Health in Bethesda, Maryland.From 1986 to 1988, she served in the U.S. Office of Disease Prevention and Health Promotion, and from 1989 to 1990 she was assistant director of the National Institute of Allergy and Infectious Diseases at NIH, where her ...

Chembio Diagnostics, Inc. (CEMI.OB), a company that develops, manufactures, and markets simple and cost-effective testing devices, recently announced its financial results for the third quarter 2008. Chembio is focused on high-quality rapid testing kits for detecting diseases such as HIV and tuberculosis to the worldwide market.

In the third quarter 2008, Chembio recognized total revenue of $3.52 million, which is a 52% increase compared to the same period in 2007 of $2.31 million. The company’s positive revenue numbers were mainly due to the company’s strong sales of its HIV testing kits in the U.S. and in Africa along with its increased sales in Brazil, Asia, and the Middle East.

The company increased its technical and manufacturing capacity over the third quarter, while reducing SG&A expenses. Chembio managed to reduce overall SG&A costs by 3.5% over the period. By controlling its SG&A costs and increasing its sales numbers, the company was

...